Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA®️ for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary disease, based on review of data from QUILT-3.032 Adding to existing…
